- Home
- DKNG vs ABVX Comparison
DKNG vs ABVX Comparison
Compare DKNG & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKNG | ABVX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.9B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DKNG | ABVX |
|---|---|---|
| Price | $26.08 | $116.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 31 | 13 |
| Target Price | $38.10 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 12.5M | 811.8K |
| Earning Date | 05-07-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.05 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,054,525,000.00 | N/A |
| Revenue This Year | $15.47 | $52.14 |
| Revenue Next Year | $13.09 | $4,132.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.99 | N/A |
| 52 Week Low | $20.46 | $69.81 |
| 52 Week High | $48.78 | $148.83 |
Technical Indicators
Market Signals| Indicator | DKNG | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 40.08 |
| Support Level | $23.95 | $107.67 |
| Resistance Level | $26.86 | $129.00 |
| Average True Range (ATR) | 1.28 | 3.79 |
| MACD | 0.22 | -1.19 |
| Stochastic Oscillator | 86.39 | 4.21 |
Price Performance
Historical ComparisonAbout DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. With its predictive market launch in 2025, DraftKings is now live with online or retail sports betting in most all states and i-gaming in five states, with both products available to around 40% of Canada's population. In 2025, sports revenue was 63% of total sales, i-gaming 30%, and fantasy and lottery 7%.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.